Toggle navigation
About Us
Who We Are
Management Team
Founders
Board of Directors
Core Values
Our Approach
& Programs
Gene Therapy
Pipeline
Our Programs
Manufacturing
Publications & Presentations
Patients
& Caregivers
Parkinson’s Disease FAQ
Parkinson’s Disease Clinical Trial
Patient Resources
Expanded Access Policy
For Investors
& Media
Investor Overview
Stock information
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Annual Reports
Analyst Coverage
Investor FAQs
Contact
Join
Our Team
Who We Are
Benefits
Join Us
Awards
Contact
Toggle navigation
About Us
Who We Are
Management Team
Founders
Board of Directors
Core Values
Our Approach
& Programs
Gene Therapy
Pipeline
Our Programs
Manufacturing
Publications & Presentations
Patients
& Caregivers
Parkinson’s Disease FAQ
Parkinson’s Disease Clinical Trial
Patient Resources
Expanded Access Policy
For Investors
& Media
Investor Overview
Stock information
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Annual Reports
Analyst Coverage
Investor FAQs
Contact
Join
Our Team
Who We Are
Benefits
Join Us
Awards
Contact
INTRAPUTAMINAL AADC GENE THERAPY (VY-AADC01) FOR ADVANCED PARKINSON’S DISEASE: INTERIM RESULTS OF A PHASE 1B TRIAL